MARKET

PCRX

PCRX

Pacira Biosciences Inc
NASDAQ
30.61
-0.21
-0.68%
After Hours: 31.21 +0.6 +1.96% 17:12 05/20 EDT
OPEN
30.70
PREV CLOSE
30.82
HIGH
30.90
LOW
30.24
VOLUME
680.31K
TURNOVER
0
52 WEEK HIGH
42.63
52 WEEK LOW
25.33
MARKET CAP
1.42B
P/E (TTM)
23.62
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at PCRX last week (0513-0517)?
Weekly Report · 22h ago
Weekly Report: what happened at PCRX last week (0506-0510)?
Weekly Report · 05/13 09:11
Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
Pacira BioSciences, Inc. Shares rose 9.3% following the release of its first-quarter results last week. Revenues were in line with forecasts, but statutory earnings per share came in 17% lower than expected. The analysts are forecasting revenues to slow to US$694.6m in 2024. The consensus price target of US$45.36 remains for the company.
Simply Wall St · 05/10 11:40
Pacira BioSciences announces pricing of convertible senior notes due 2029
Pacira BioSciences announces pricing of convertible senior notes due 2029 in a private placement to qualified institutional buyers. The notes will bear interest at a fixed rate of 2.125% per year. Pacira also granted option to purchase additional $37.5 million aggregate principal amount of notes.
Seeking Alpha · 05/10 11:17
BRIEF-Pacira Biosciences, Announces Pricing Of $250.0 Million Aggregate Principal Amount Of 2.125% Convertible Senior Notes Due 2029
Pacira Biosciences, Announces Pricing Of $250.0 million Aggregate Principal Amount Of 2.125% Convertible Senior Notes Due 2029. The notes are due May 15, 2029 for a total of $500 million. The company is a subsidiary of Pacira Pharmaceuticals Inc.
Reuters · 05/10 11:07
PACIRA CONVERTIBLE SENIOR NOTES MATURITY SET FOR MAY 15, 2029
Reuters · 05/10 11:00
PCRX December 2025 Options Begin Trading
NASDAQ · 05/09 15:03
BRIEF-Pacira Biosciences, Inc. Announces Proposed Offering Of $250.0 Million Aggregate Principal Amount Of Convertible Senior Notes
Reuters · 05/08 20:55
More
About PCRX
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.

Webull offers Pacira Biosciences Inc stock information, including NASDAQ: PCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PCRX stock methods without spending real money on the virtual paper trading platform.